Indicator type Size of the company Total Number of companies carrying out R&D in Biotechnology Less than 250 employees 1.221 Number of companies carrying out R&D in Biotechnology 250 and more employees 156 Number of companies carrying out R&D in Biotechnology Total 1.376 % Companies by type of biotechnology used: Genetic Code Less than 250 employees 30,2 % Companies by type of biotechnology used: Genetic Code 250 and more employees 41,5 % Companies by type of biotechnology used: Genetic Code Total 31,4 % Companies by type of biotechnology used: Functional Units Less than 250 employees 42,4 % Companies by type of biotechnology used: Functional Units 250 and more employees 54,3 % Companies by type of biotechnology used: Functional Units Total 43,7 % Companies by type of biotechnology used: Cell and Tissue Culture and Engineering Less than 250 employees 21,2 % Companies by type of biotechnology used: Cell and Tissue Culture and Engineering 250 and more employees 35,9 % Companies by type of biotechnology used: Cell and Tissue Culture and Engineering Total 22,8 % Companies by type of biotechnology used: Bioprocesses Less than 250 employees 46,1 % Companies by type of biotechnology used: Bioprocesses 250 and more employees 65,3 % Companies by type of biotechnology used: Bioprocesses Total 48,3 % Companies by type of biotechnology used: Subcellular Organisms Less than 250 employees 7 % Companies by type of biotechnology used: Subcellular Organisms 250 and more employees 14,6 % Companies by type of biotechnology used: Subcellular Organisms Total 7,9 % Companies by type of biotechnology used: Bioinformatics Less than 250 employees 26,5 % Companies by type of biotechnology used: Bioinformatics 250 and more employees 32,5 % Companies by type of biotechnology used: Bioinformatics Total 27,1 % Companies by type of biotechnology used: Nanobiotechnology Less than 250 employees 11 % Companies by type of biotechnology used: Nanobiotechnology 250 and more employees 13,4 % Companies by type of biotechnology used: Nanobiotechnology Total 11,2 % Companies by type of biotechnology used: Other Less than 250 employees 18,1 % Companies by type of biotechnology used: Other 250 and more employees 14 % Companies by type of biotechnology used: Other Total 17,6 Companies in which biotechnology activities are: Main and/or exclusive Less than 250 employees 686 Companies in which biotechnology activities are: Main and/or exclusive 250 and more employees 25 Companies in which biotechnology activities are: Main and/or exclusive Total 711 Companies in which biotechnology activities are: A secondary business line Less than 250 employees 214 Companies in which biotechnology activities are: A secondary business line 250 and more employees 55 Companies in which biotechnology activities are: A secondary business line Total 270 Companies in which biotechnology activities are: A necessary tool for production Less than 250 employees 320 Companies in which biotechnology activities are: A necessary tool for production 250 and more employees 75 Companies in which biotechnology activities are: A necessary tool for production Total 395 % Companies by final application areas of biotechnology use: Human Health Less than 250 employees 48,7 % Companies by final application areas of biotechnology use: Human Health 250 and more employees 42,7 % Companies by final application areas of biotechnology use: Human Health Total 48 % Companies by final application areas of biotechnology use: Animal Health and Aquaculture Less than 250 employees 16,7 % Companies by final application areas of biotechnology use: Animal Health and Aquaculture 250 and more employees 17,9 % Companies by final application areas of biotechnology use: Animal Health and Aquaculture Total 16,9 % Companies by final application areas of biotechnology use: Food Products Less than 250 employees 28 % Companies by final application areas of biotechnology use: Food Products 250 and more employees 40,1 % Companies by final application areas of biotechnology use: Food Products Total 29,4 % Companies by final application areas of biotechnology use: Agriculture and Forestry Less than 250 employees 26,1 % Companies by final application areas of biotechnology use: Agriculture and Forestry 250 and more employees 22,6 % Companies by final application areas of biotechnology use: Agriculture and Forestry Total 25,7 % Companies by final application areas of biotechnology use: Environment Less than 250 employees 17,9 % Companies by final application areas of biotechnology use: Environment 250 and more employees 18,9 % Companies by final application areas of biotechnology use: Environment Total 18 % Companies by final application areas of biotechnology use: Industry Less than 250 employees 12,6 % Companies by final application areas of biotechnology use: Industry 250 and more employees 16,5 % Companies by final application areas of biotechnology use: Industry Total 13 R&D personnel in Biotechnology (PP) Less than 250 employees 10.421 R&D personnel in Biotechnology (PP) 250 and more employees 6.836 R&D personnel in Biotechnology (PP) Total 17.257 R&D personnel in Biotechnology (PP): Research personnel Less than 250 employees 6.087 R&D personnel in Biotechnology (PP): Research personnel 250 and more employees 3.108 R&D personnel in Biotechnology (PP): Research personnel Total 9.195 R&D personnel in Biotechnology (PP): Technical and auxiliary personnel Less than 250 employees 4.333 R&D personnel in Biotechnology (PP): Technical and auxiliary personnel 250 and more employees 3.728 R&D personnel in Biotechnology (PP): Technical and auxiliary personnel Total 8.061 R&D personnel in Biotechnology (PP). Women Less than 250 employees 5.700 R&D personnel in Biotechnology (PP). Women 250 and more employees 4.280 R&D personnel in Biotechnology (PP). Women Total 9.980 R&D personnel in Biotechnology (PP). Women: Research personnel Less than 250 employees 3.359 R&D personnel in Biotechnology (PP). Women: Research personnel 250 and more employees 1.863 R&D personnel in Biotechnology (PP). Women: Research personnel Total 5.222 R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel Less than 250 employees 2.341 R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel 250 and more employees 2.417 R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel Total 4.758 R&D personnel in Biotechnology (FTE) Less than 250 employees 7.562,8 R&D personnel in Biotechnology (FTE) 250 and more employees 5.320,6 R&D personnel in Biotechnology (FTE) Total 12.883,4 R&D personnel in Biotechnology (FTE): Research personnel Less than 250 employees 4.665,3 R&D personnel in Biotechnology (FTE): Research personnel 250 and more employees 2.437,9 R&D personnel in Biotechnology (FTE): Research personnel Total 7.103,2 R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel Less than 250 employees 2.897,4 R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel 250 and more employees 2.882,8 R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel Total 5.780,2 R&D personnel in Biotechnology (FTE). Women Less than 250 employees 4.222 R&D personnel in Biotechnology (FTE). Women 250 and more employees 3.378,6 R&D personnel in Biotechnology (FTE). Women Total 7.600,6 R&D personnel in Biotechnology (FTE). Women: Research personnel Less than 250 employees 2.605,7 R&D personnel in Biotechnology (FTE). Women: Research personnel 250 and more employees 1.451,3 R&D personnel in Biotechnology (FTE). Women: Research personnel Total 4.057 R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel Less than 250 employees 1.616,3 R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel 250 and more employees 1.927,3 R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel Total 3.543,7 Expenditure on internal R&D in Biotechnology (thousands of euros) Less than 250 employees 794.091 Expenditure on internal R&D in Biotechnology (thousands of euros) 250 and more employees 489.255 Expenditure on internal R&D in Biotechnology (thousands of euros) Total 1.283.346 1) By type of expenditure: Current expenditure Less than 250 employees 715.652 1) By type of expenditure: Current expenditure 250 and more employees 464.535 1) By type of expenditure: Current expenditure Total 1.180.187 1.1) Labour expenditure of research personnel Less than 250 employees 235.238 1.1) Labour expenditure of research personnel 250 and more employees 137.183 1.1) Labour expenditure of research personnel Total 372.421 1.2) Labour expenditure of technical and auxiliary personnel Less than 250 employees 113.075 1.2) Labour expenditure of technical and auxiliary personnel 250 and more employees 116.659 1.2) Labour expenditure of technical and auxiliary personnel Total 229.734 1.3) Other current expenditure Less than 250 employees 367.339 1.3) Other current expenditure 250 and more employees 210.693 1.3) Other current expenditure Total 578.032 2) By type of expenditure: Capital expenditure Less than 250 employees 78.439 2) By type of expenditure: Capital expenditure 250 and more employees 24.720 2) By type of expenditure: Capital expenditure Total 103.159 2.1) Land and buildings Less than 250 employees 8.547 2.1) Land and buildings 250 and more employees 2.342 2.1) Land and buildings Total 10.889 2.2) Equipment and tools Less than 250 employees 40.395 2.2) Equipment and tools 250 and more employees 18.809 2.2) Equipment and tools Total 59.204 2.3) Acquisition of specific R&D software Less than 250 employees 4.415 2.3) Acquisition of specific R&D software 250 and more employees 1.208 2.3) Acquisition of specific R&D software Total 5.623 2.4) Other R&D-specific IP products Less than 250 employees 25.082 2.4) Other R&D-specific IP products 250 and more employees 2.360 2.4) Other R&D-specific IP products Total 27.442 1.1) By origin of funds: Own funds Less than 250 employees 548.276 1.1) By origin of funds: Own funds 250 and more employees 339.251 1.1) By origin of funds: Own funds Total 887.527 1.2) By origin of funds: Funds from the Business sector Less than 250 employees 96.237 1.2) By origin of funds: Funds from the Business sector 250 and more employees 47.667 1.2) By origin of funds: Funds from the Business sector Total 143.903 1.3) By origin of funds: Funds from the Public Administration sector Less than 250 employees 98.923 1.3) By origin of funds: Funds from the Public Administration sector 250 and more employees 27.623 1.3) By origin of funds: Funds from the Public Administration sector Total 126.546 1.4) By origin of funds: Funds from the Higher Education sector Less than 250 employees 94 1.4) By origin of funds: Funds from the Higher Education sector 250 and more employees 0 1.4) By origin of funds: Funds from the Higher Education sector Total 94 1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector Less than 250 employees 2.684 1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector 250 and more employees 9.939 1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector Total 12.623 1.6) By origin of funds: Funds from the rest of the world Less than 250 employees 47.877 1.6) By origin of funds: Funds from the rest of the world 250 and more employees 64.776 1.6) By origin of funds: Funds from the rest of the world Total 112.652 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros) Less than 250 employees 76.773 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros) 250 and more employees 60.659 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros) Total 137.432 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain Less than 250 employees 38.607 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain 250 and more employees 49.521 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain Total 88.127 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world Less than 250 employees 38.166 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world 250 and more employees 11.139 Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world Total 49.305 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital Less than 250 employees 46,3 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital 250 and more employees 23,2 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital Total 43,7 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information Less than 250 employees 16,3 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information 250 and more employees 15,5 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information Total 16,2 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources Less than 250 employees 24,6 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources 250 and more employees 16 % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources Total 23,7 % Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain Less than 250 employees 14,4 % Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain 250 and more employees 14,5 % Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain Total 14,5 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets Less than 250 employees 19 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets 250 and more employees 10,5 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets Total 18,1 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels Less than 250 employees 20,4 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels 250 and more employees 12,9 % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels Total 19,6 % Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception Less than 250 employees 18,9 % Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception 250 and more employees 21,2 % Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception Total 19,1 % Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements Less than 250 employees 51 % Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements 250 and more employees 40,8 % Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements Total 49,8 % Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost Less than 250 employees 61 % Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost 250 and more employees 46,8 % Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost Total 59,4 % Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting Less than 250 employees 23,7 % Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting 250 and more employees 11 % Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting Total 22,3 % Companies with international revenues related to biotechnology activities Less than 250 employees 23,6 % Companies with international revenues related to biotechnology activities 250 and more employees 22,7 % Companies with international revenues related to biotechnology activities Total 23,6 % Companies representing international revenues related to biotechnology activities Less than 250 employees 6,9 % Companies representing international revenues related to biotechnology activities 250 and more employees 1 % Companies representing international revenues related to biotechnology activities Total 1,5 % International revenues related to biotechnology activities distributed in: Revenues from the EU Less than 250 employees 50 % International revenues related to biotechnology activities distributed in: Revenues from the EU 250 and more employees 62,8 % International revenues related to biotechnology activities distributed in: Revenues from the EU Total 57,6 % International revenues related to biotechnology activities distributed in: Revenues from the rest of the world Less than 250 employees 50 % International revenues related to biotechnology activities distributed in: Revenues from the rest of the world 250 and more employees 37,2 % International revenues related to biotechnology activities distributed in: Revenues from the rest of the world Total 42,4 % International revenues related to biotechnology activities by classification: International trade in goods and services Less than 250 employees 91,4 % International revenues related to biotechnology activities by classification: International trade in goods and services 250 and more employees 76,2 % International revenues related to biotechnology activities by classification: International trade in goods and services Total 82,3 % International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain Less than 250 employees 4,5 % International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain 250 and more employees 20,6 % International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain Total 14,1 % International revenues related to biotechnology activities by classification: Subsidies from external sources Less than 250 employees 1 % International revenues related to biotechnology activities by classification: Subsidies from external sources 250 and more employees 1,8 % International revenues related to biotechnology activities by classification: Subsidies from external sources Total 1,5 % International revenues related to biotechnology activities by classification: Other Less than 250 employees 3,1 % International revenues related to biotechnology activities by classification: Other 250 and more employees 1,4 % International revenues related to biotechnology activities by classification: Other Total 2,1